Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis

Brown, DA, Stephan, C, Ward, RL, Law, M, Hunter, M, Bauskin, AR, Amin, J, Jung, K, Diamandis, EP, Hampton, GM, Russell, PJ, Giles, GG and Breit, SN (2006) Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clinical Cancer Research, 12 1: 89-96. doi:10.1158/1078-0432.CCR-05-1331


Author Brown, DA
Stephan, C
Ward, RL
Law, M
Hunter, M
Bauskin, AR
Amin, J
Jung, K
Diamandis, EP
Hampton, GM
Russell, PJ
Giles, GG
Breit, SN
Title Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis
Journal name Clinical Cancer Research   Check publisher's open access policy
ISSN 1078-0432
Publication date 2006-01-01
Year available 2006
Sub-type Article (original research)
DOI 10.1158/1078-0432.CCR-05-1331
Open Access Status Not yet assessed
Volume 12
Issue 1
Start page 89
End page 96
Total pages 8
Publisher AMER ASSOC CANCER RESEARCH
Language eng
Subject 1306 Cancer Research
2730 Oncology
Abstract Purpose: Current serum testing for the detection of prostate cancer (PCa) lacks specificity. On diagnosis, the optimal therapeutic pathway is not clear and tools for adequate risk assessment of localized PCa progression are not available. This leads to a significant number of men having unnecessary diagnostic biopsies and surgery. A search for novel tumor markers identified macrophage inhibitory cytokine 1 (MIC-1) as a potentially useful marker. Follow-up studies revealed MIC-1 overexpression in local and metastatic PCa whereas peritumoral interstitial staining for MIC-1 identified lower-grade tumors destined for recurrence. Consequently, we sought to assess serum MIC-1 measurement as a diagnostic tool. Experimental Design: Using immunoassay determination of serum MIC-1 concentration in 1,000 men, 538 of whom had PCa, we defined the relationship of MIC-1 to disease variables. A diagnostic algorithm (MIC-PSA score) based on serum levels of MIC-1, total serum prostate-specific antigen, and percentage of free prostate-specific antigen was developed. Results: Serum MIC-1 was found to be an independent predictor of the presence of PCa and tumors with a Gleason sum ≥7. We validated the MIC-PSA score in a separate population and showed an improved specificity for diagnostic blood testing for PCa over percentage of free prostate-specific antigen, potentially reducing unnecessary biopsies by 27%. Conclusions: Serum MIC-1 is an independent marker of the presence of PCa and tumors with a Gleason sum of ≥7. The use of serum MIC-1 significantly increases diagnostic specificity and may be a future tool in the management of PCa.
Keyword Oncology
Oncology
ONCOLOGY
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collection: Scopus Import - Archived
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 76 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 83 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 11 Feb 2015, 21:10:11 EST by Ms Kate Rowe